GLP-1 medications are popular these days, but the body already naturally produces its own GLP-1. Dr. Mercola, a ...

Novo Nordisk invests €432M ($506M) in Athlone, Ireland to boost oral glucagon-like peptide-1 manufacturing capacity for global markets by 2028.

RFK Jr. announced his plan on the latest Joe Rogan Experience podcast, which aired on Friday. He specifically intends to ...

Preliminary study finds GLP-1 drugs (semaglutide, etc.) are associated with 10% fewer emergency visits and lower medication use for chronic migraine patients.

A recent study found that combing GLP-1 drugs with healthy lifestyle habits may help reduce cardiovascular risk in people with diabetes.

Social media influencers and supplement companies have stoked concerns, but experts say the issue is a lot more complicated.

Two studies examining the use of glucagon-like peptide-1 receptor agonists, including semaglutide, have found short- and long-term associations in orthopedic postoperative outcomes and general ...

In this systematic review and meta-analysis, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) produced greater weight loss among ...

GLP1-RA use may be linked to improved overall survival, but not improved disease-free survival, in breast cancer survivors, researchers report.

Research presented at AAAAI 2026 suggests GLP-1 RAs may provide clinical benefits for asthma management in patients with excess body weight.

The GLP-1 effect is redefining the consumption equation in 2026 and beyond. Consumers will eat less, but will demand more protein, better nutrition, and smart portion sizes. Companies that understand ...

Chronic migraine sufferers taking GLP-1 drugs were about 10% less likely to need ER care for a migraine attack compared to those taking a standard first-line migraine drug, researchers are scheduled ...